Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Michael Raab
AddedMar 31, 2024
UpdatedMay 31, 2026
Michael Raab

Michael Raab

Board Member, Tempest Therapeutics

CrunchbaseLinkedIn

Michael Raab's Career

Tempest Therapeutics
Tempest Therapeutics

South San Francisco, CA, US

Board Member· Board
Ardelyx
Ardelyx

Fremont, CA, US

Board Member· Board
Amicus Therapeutics
Amicus Therapeutics

Cranbury, NJ, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Michael Raab's Career

Tempest Therapeutics
Tempest Therapeutics
Acquired$90M02011South San Francisco, CA, US
Board Member· Board

Leadership at Tempest Therapeutics

Bradley BolzonBradley BolzonBoard Member
Ronit SimantovRonit SimantovBoard Member
Tom WoiwodeTom WoiwodeBoard Member
Christine PellizzariChristine PellizzariBoard Member
Geoff NicholGeoff NicholBoard Member
Robert WeisskoffRobert WeisskoffBoard Member

Similar to Tempest Therapeutics

PineTree TherapeuticsPineTree TherapeuticsCambridge, MA, USBiotech Therapiesest. 2019PineTree TherapeuticsCambridge, MA, US · est. 2019

PineTree Therapeutics: Innovating biotech therapies in Oncology and Immuno-oncology.

Series B · $23.5M17
Terpenoid TherapeuticsTerpenoid TherapeuticsCoralville, IA, USDrug Developmentest. 2005Terpenoid TherapeuticsCoralville, IA, US · est. 2005

Terpenoid Therapeutics Inc: Innovating cancer cure through biotech-driven drug discovery and development.

Pre-Seed · $1M30
Window TherapeuticsWindow TherapeuticsBoston, MA, USCancer Treatmentest. 2021Window TherapeuticsBoston, MA, US · est. 2021

Window Therapeutics: A biotech firm innovating targeted cancer treatments for unmet patient needs.

Angel · $256k4
Fuse BiotherapeuticsFuse BiotherapeuticsLos Angeles, CA, USTherapeuticsest. 2021Fuse BiotherapeuticsLos Angeles, CA, US · est. 2021

FuseBio: Innovating immune-modulating therapeutics for cancer treatment.

Seed · $9.5M5
Ardelyx
Ardelyx
Public$471.4M1332007Fremont, CA, US
Board Member· Board

Leadership at Ardelyx

Jan LundbergJan LundbergBoard Member
Rick RodgersRick RodgersBoard Member
Peter G. SchultzPeter G. SchultzCo-Founder
Geoffrey A. BlockGeoffrey A. BlockBoard Member
Dave MottDave MottBoard Member
Onaiza Cadoret-ManierOnaiza Cadoret-ManierBoard Member

Similar to Ardelyx

Elcelyx TherapeuticsElcelyx TherapeuticsSan Diego, CA, USPharmaceuticalsest. 2010Elcelyx TherapeuticsSan Diego, CA, US · est. 2010

Elcelyx Therapeutics develops nutrient-based solutions for weight management and metabolic disorders.

Series E · $96.8M9
Amylyx PharmaceuticalsAmylyx PharmaceuticalsCambridge, MA, USTherapeuticsest. 2014Amylyx PharmaceuticalsCambridge, MA, US · est. 2014

Amylyx Pharmaceuticals: A global biopharmaceutical firm innovating therapies for ALS and neurodegenerative diseases.

Public · $448.5M262
PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k
Gilead SciencesGilead SciencesFoster City, CA, USPharmaceuticals, Therapiesest. 1987Gilead SciencesFoster City, CA, US · est. 1987

Gilead Sciences: An American biopharmaceutical firm innovating therapies for critical diseases.

Public · $2B17k
Amicus Therapeutics
Amicus Therapeutics
Public$2.4B4842002Cranbury, NJ, US
Board Member· Board

Leadership at Amicus Therapeutics

John CrowleyJohn CrowleyBoard Member
Lynn D. BleilLynn D. BleilBoard Member
Burke W. WhitmanBurke W. WhitmanBoard Member
Michael A. KellyMichael A. KellyBoard Member
Margaret McGlynnMargaret McGlynnBoard Member
Bradley CampbellBradley CampbellCEO

Michael Raab's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Michael Raab

Dominique CharmotDominique CharmotCo-Founder · ArdelyxRami ElghandourRami ElghandourBoard Member · 3DegreesMichael ArtingerMichael ArtingerBoard Member · Solaris VaccinesRichard LowenthalRichard LowenthalCo-Founder & CEO · ARS PharmaceuticalsAllan WillAllan WillCo-Founder · Split Rock Partners